Thrombolytic therapy for stroke

Thomas G Brott, J. Broderick, R. Kothari

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic stroke following tissue plasminogen activator or streptokinase. In the setting of ischemic stroke, recanalization rates following intravenous tissue plasminogen activator have been modest and at least partly dependent on clot size. Conclusions regarding clinical benefit will depend on the results of multicenter randomized trials that should available in 1995. Studies of locally administered intra-arterial thrombolytic therapy demonstrate high rates of clot lysis, but clinical benefits have yet to be established. The results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage. Thrombolytic therapy in the study of subarachnoid hemorrhage is under active investigation.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalCurrent Opinion in Neurology
Volume7
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Fibrinolytic Agents
Thrombolytic Therapy
Stroke
Tissue Plasminogen Activator
Streptokinase
Intracranial Hemorrhages
Subarachnoid Hemorrhage
Multicenter Studies
Thrombosis
Myocardial Infarction
Pharmacology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Brott, T. G., Broderick, J., & Kothari, R. (1994). Thrombolytic therapy for stroke. Current Opinion in Neurology, 7(1), 25-35.

Thrombolytic therapy for stroke. / Brott, Thomas G; Broderick, J.; Kothari, R.

In: Current Opinion in Neurology, Vol. 7, No. 1, 1994, p. 25-35.

Research output: Contribution to journalArticle

Brott, TG, Broderick, J & Kothari, R 1994, 'Thrombolytic therapy for stroke', Current Opinion in Neurology, vol. 7, no. 1, pp. 25-35.
Brott TG, Broderick J, Kothari R. Thrombolytic therapy for stroke. Current Opinion in Neurology. 1994;7(1):25-35.
Brott, Thomas G ; Broderick, J. ; Kothari, R. / Thrombolytic therapy for stroke. In: Current Opinion in Neurology. 1994 ; Vol. 7, No. 1. pp. 25-35.
@article{e77a8401ae7f43b380aa7ce931624c3f,
title = "Thrombolytic therapy for stroke",
abstract = "The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic stroke following tissue plasminogen activator or streptokinase. In the setting of ischemic stroke, recanalization rates following intravenous tissue plasminogen activator have been modest and at least partly dependent on clot size. Conclusions regarding clinical benefit will depend on the results of multicenter randomized trials that should available in 1995. Studies of locally administered intra-arterial thrombolytic therapy demonstrate high rates of clot lysis, but clinical benefits have yet to be established. The results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage. Thrombolytic therapy in the study of subarachnoid hemorrhage is under active investigation.",
author = "Brott, {Thomas G} and J. Broderick and R. Kothari",
year = "1994",
language = "English (US)",
volume = "7",
pages = "25--35",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Thrombolytic therapy for stroke

AU - Brott, Thomas G

AU - Broderick, J.

AU - Kothari, R.

PY - 1994

Y1 - 1994

N2 - The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic stroke following tissue plasminogen activator or streptokinase. In the setting of ischemic stroke, recanalization rates following intravenous tissue plasminogen activator have been modest and at least partly dependent on clot size. Conclusions regarding clinical benefit will depend on the results of multicenter randomized trials that should available in 1995. Studies of locally administered intra-arterial thrombolytic therapy demonstrate high rates of clot lysis, but clinical benefits have yet to be established. The results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage. Thrombolytic therapy in the study of subarachnoid hemorrhage is under active investigation.

AB - The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic stroke following tissue plasminogen activator or streptokinase. In the setting of ischemic stroke, recanalization rates following intravenous tissue plasminogen activator have been modest and at least partly dependent on clot size. Conclusions regarding clinical benefit will depend on the results of multicenter randomized trials that should available in 1995. Studies of locally administered intra-arterial thrombolytic therapy demonstrate high rates of clot lysis, but clinical benefits have yet to be established. The results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage. Thrombolytic therapy in the study of subarachnoid hemorrhage is under active investigation.

UR - http://www.scopus.com/inward/record.url?scp=0027979459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027979459&partnerID=8YFLogxK

M3 - Article

C2 - 8173673

AN - SCOPUS:0027979459

VL - 7

SP - 25

EP - 35

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 1

ER -